We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ion Beam Applications SA | EU:IBAB | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.06 | 0.46% | 13.20 | 13.12 | 13.50 | 13.86 | 13.12 | 13.56 | 38,751 | 16:40:00 |
FY23 results meeting to take place as a hybrid event on Thursday, 21 March 2024 at 3pm CET
Louvain-la-Neuve, Belgium, 26 February 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2023 on Thursday, 21 March 2024 at 7am CET.
Conference Call Information
IBA’s management team will host a hybrid event, including a conference call and webcast conducted in English, to present the half year results, followed by a Q&A session.
The conference call will be held on Thursday, 21 March 2024 at 3pm CET / 2pm GMT / 10am ET / 7am PT as a Teams webinar and can be accessed online on this link.
If you would like to join by phone only, please dial (Phone conference ID 204 708 166#):
Belgium: +32 2 890 97 20UK: +44 20 3321 5200NL: +31 20 708 6901LU: +352 27 87 00 02US: +1 347-991-7591FR: +33 1 70 99 53 51
The presentation will be available on IBA’s investor relations website and on https://www.iba-worldwide.com/full-year-results-2023-press-release-and-conference-call shortly before the call.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
For participants who do not have the Teams application installed, please follow the process described in this link to access the conference.
ENDS
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
CONTACTS
Soumya ChandramouliChief Financial Officer+32 10 475 890Investorrelations@iba-group.com
Olivier LechienCorporate Communication Director+32 10 475 890communication@iba-group.com
ICR ConsiliumAmber Fennell, Matthew Neal, Lucy Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
Attachment
1 Year Ion Beam Applications Chart |
1 Month Ion Beam Applications Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions